The adipocyte in insulin resistance: Key molecules and the impact of the thiazolidinediones

Trends in Endocrinology and Metabolism

Volumn 14, Issue 3, 2003, Pages 137-145

  Arner, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIDIABETIC AGENT; FATTY ACID; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RESISTIN; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; CELL FUNCTION; DRUG EFFECT; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID TRANSPORT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037732481     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(03)00024-9     Document Type: Review

References (65)

1. Mokdad, A.H. et al. (2001) The continuing epidemics of obesity and diabetes in the United States. J. Am. Med. Assoc. 286, 1195-1200
2. Mokdad, A.H. et al. (2000) Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23, 1278-1283
3. Dunstan, D.W. et al. (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25, 829-834
4. Deckelbaum, R.J. and Williams, C.L. (2001) Childhood obesity: the health issue. Obes. Res. 9, 239S-243S
5. Rocchini, A.P. (2002) Childhood obesity and a diabetes epidemic. N. Engl. J. Med. 346, 854-855
6. Sims, E.A. et al. (1973) Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res. 29, 457-496
7. Beck-Nielsen, H. et al. (1979) Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol. (Copenh.) 90, 103-112
8. Freidenberg, G.R. et al. (1988) Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J. Clin. Invest. 82, 1398-1406
9. Bak, J.F. et al. (1992) In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment. Diabetologia 35, 777-784
10. DeFronzo, R.A. et al. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318-368
11. Hotamisligil, G.S. (2000) Molecular mechanisms of insulin resistance and the role of the adipocyte. Int. J. Obes. Relat. Metab. Disord. 24, S23-S27
12. Bergman, R.N. et al. (2001) Central role of the adipocyte in the metabolic syndrome. J. Investig. Med. 49, 119-126
13. Arner, P. (1997) Regional adipocity in man. J. Endocrinol. 155, 191-192
14. Trayhurn, P. and Beattie, J.H. (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60, 329-339
15. Arner, P. (2001) Free fatty acids - do they play a central role in type 2 diabetes? Diabetes Obes. Metab. 3, 11-19
16. Rhodes, C.J. and White, M.F. (2002) Molecular insights into insulin action and secretion. Eur. J. Clin. Invest. 32, 3-13
17. Kahn, B.B. and Flier, J.S. (2000) Obesity and insulin resistance. J. Clin. Invest. 106, 473-481
18. Summers, S.A. et al. (2000) Insulin signaling in the adipocyte. Int. J. Obes. Relat. Metab. Disord. 24, S67-S70
19. Smith, U. et al. (1999) Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. Ann. New York Acad. Sci. 892, 119-126
20. Sethi, J.K. and Hotamisligil, G.S. (1999) The role of TNFα in adipocyte metabolism. Semin. Cell Dev. Biol. 10, 19-29
21. Löfgren, P. et al. (2000) Secretion of tumor necrosis factor-α shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 49, 688-692
22. Greenberg, A.S. and McDaniel, M.L. (2002) Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur. J. Clin. Invest. 32, 24-34
23. Carvalho, E. et al. (1999) Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J. 13, 2173-2178
24. Arner, P. (2002) Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab. Res. Rev. 18, S5-S9
25. Boden, G. and Shulman, G.I. (2002) Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur. J. Clin. Invest. 32, 14-23
26. Idris, I. et al. (2002) Insulin action in skeletal muscle: isozyme-specific effects of protein kinase C. Ann. New York Acad. Sci. 967, 176-182
27. Kelley, D.E. (2002) Skeletal muscle triglycerides: an aspect of regional adiposity and insulin resistance. Ann. New York Acad. Sci. 967, 135-145
28. Holst, D. and Grimaldi, P.A. (2002) New factors in the regulation of adipose differentiation and metabolism. Curr. Opin. Lipidol. 13, 241-245
29. Steppan, C.M. et al. (2001) The hormone resistin links obesity to diabetes. Nature 409, 307-312
30. Girard, J. (1997) Is leptin the link between obesity and insulin resistance? Diabetes Metab. 23, 16-24
31. Trayhurn, P. et al. (1999) Leptin: fundamental aspects. Int. J. Obes. Relat. Metab. Disord. 23, 22-28
32. Cnop, M. et al. (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51, 1005-1015
33. Spiegelman, B.M. (1998) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514
34. Walczak, R. and Tontonoz, P. (2002) PPARadigms and PPARadoxes. Expanding roles for PPARγ in the control of lipid metabolism. J. Lipid Res. 43, 177-186
35. Masamune, A. et al. (2002) Ligands of peroxisome proliferatoractivated receptor-γ block activation of pancreatic stellate cells. J. Biol. Chem. 277, 141-147
36. Lebovitz, H.E. (2002) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev. 18 (Suppl. 2), S23-S29
37. Lebovitz, H.E. et al. (2001) Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 86, 280-288
38. Miyazaki, Y. et al. (2002) Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25, 517-523
39. Adams, M. et al. (1997) Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100, 3149-3153
40. Van Harmelen, V. et al. (2002) Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 51, 2029-2036
41. Kelley, D.E. et al. (2002) Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus. Diabetes 51, A35
42. Virtanen, K.A. et al. (2002) Different effects of rosiglitazone and metformin on adipose tissue glucose uptake in type 2 diabetes. Diabetes 51, A145
43. Banerji, M. et al. (2001) Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus. Diabetes 50, A90
44. Wagstaff, A.J. and Goa, K.L. (2002) Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62, 1805-1837
45. McTernan, P.G. et al. (2002) Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 51, 1493-1498
46. Tan, S.A. et al. (2002) Comparative study of the effects of rosiglitazone and pioglitazone on interferon, tumor necrosis factor, interleukin-1, interleukin-4, interleukin-6 and C-reactive protein in diabetic patients with atherosclerosis. Diabetes 51, A595
47. Fonseca, V. et al. (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J. Am. Med. Assoc. 283, 1695-1702
48. Wolffenbuttel, B.H. et al. (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet. Med. 17, 40-47
49. Zinman, B. (2001) PPARγ agonists in type 2 diabetes: how far have we come from 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes. Metab. 3, S34-S43
50. Mayerson, A.B. et al. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797-802
51. Yang, W.S. et al. (2002) Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25, 376-380
52. Plutzky, J. et al. (2002) Atherosclerosis in type 2 diabetes and insulin resistance: mechanistic links and therapeutic targets. J. Diabetes Comp. 16, 401-415
53. Hartman, H.B. et al. (2002) Mechanisms regulating adipocyte expression of resistin. J. Biol. Chem. 277, 19754-19761
54. McTernan, P.G. et al. (2002) The regulation of resistin expression by insulin and rosiglitazone in human abdominal subcutaneous adipocytes. Diabetes 51, A88
55. Smith, U. (2002) Resistin - resistant to defining its role. Obes. Res. 10, 61-62
56. Shrago, E. et al. (1971) Comparative aspects of lipogenesis in mammalian tissues. Metabolism 20, 54-62
57. Lafontan, M. et al. (1997) Adrenergic regulation of adipocyte metabolism. Hum. Reprod. 12, 6-20
58. Björnholm, M. et al. (2002) Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans. Diabetologia 45, 1697-1702
59. Mohamed-Ali, V. et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J. Clin. Endocrinol. Metab. 82, 4196-4200
60. Rydén, M. et al. (2002) Mapping of early signaling events in tumor necrosis factor-α-mediated lipolysis in human fat cells. J. Biol. Chem. 277, 1085-1091
61. Laurell, H. et al. (1997) Species-specific alternative splicing generates a catalytically inactive form of human hormone-sensitive lipase. Biochem. J. 328, 137-143
62. Ek, I. et al. (2002) A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 51, 484-492
63. Cannon, B. et al. (1998) Brown adipose tissue. More than an effector of thermogenesis? Ann. New York Acad. Sci. 856, 171-187
64. Arner, P. (1998) Not all fat is alike. Lancet 351, 1301-1302
65. Björnholm, M. et al. (2002) Insulin signal transduction and glucose transport in human adipocytes: effects of obesity and low calorie diet. Diabetologia 45, 1128-1135